M Sextro

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

H Tesch, D Hasenclever, M Sieber, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.